Join to View Full Profile
2600 Research Center DrSte ABlacksburg, VA 24060
Phone+1 540-381-5291
Fax+1 540-953-4506
Dr. Goldschmidt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Rochester Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2005- University of Rochester Medical CenterFellowship, Geriatric Medicine (Internal Medicine), 2002 - 2003
- University of Rochester Medical CenterResidency, Internal Medicine, 1999 - 2002
University of North Carolina at Chapel Hill School of MedicineClass of 1998
Certifications & Licensure
VA State Medical License 2005 - 2026
NY State Medical License 2001 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients Start of enrollment: 2022 Apr 12
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
- Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Start of enrollment: 2020 Sep 29
Publications & Presentations
PubMed
- 1 citationsCabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b ...Joel W Neal, Armando Santoro, Maria Gonzalez-Cao, Farah Louise Lim, Bruno Fang
JTO Clinical and Research Reports. 2024-10-01 - Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations Previously Treated with Plati...Jerome H Goldschmidt, Wan-Yu Tseng, Yunfei Wang, Janet Espirito, Anupama Vasudevan
Drugs - Real World Outcomes. 2024-09-01 - 1 citationsOutcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer.Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli
Immunotherapy. 2024-04-01
Press Mentions
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)August 2nd, 2023
Research History
- Site research leaderMedical director of research at Blue Ridge Cancer Care2017 - Present
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
